MG
SRDX

Michael Gelband’s Surmodics SRDX Stock Holding History

Michael Gelband’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,379
Closed -$308K – 1991
2025
Q2 		$308K Sell
10,379
-10,064
-49% -$290K ﹤0.01% 1241
2025
Q1 		$624K Sell
20,443
-30,962
-60% -$1.04M 0.01% 1060
2024
Q4 		$2.04M Sell
51,405
-13,529
-21% -$526K 0.01% 697
2024
Q3 		$2.52M Buy
+64,934
New +$2.63M 0.02% 642
2024
Q1 		– Sell
-10,410
Closed -$378K – 1940
2023
Q4 		$378K Buy
10,410
+575
+6% +$18.8K ﹤0.01% 1111
2023
Q3 		$316K Buy
+9,835
New +$334K ﹤0.01% 1404
2020
Q3 		– Sell
-5,375
Closed -$232K – 2203
2020
Q2 		$232K Buy
+5,375
New +$203K 0.01% 1442

Other funds holding SRDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's SRDX Position: Q3 2025 in Review

Michael Gelband sold out of Surmodics (SRDX) in Q3 2025, closing a stake of 10,379 shares — an estimated $308K sold.

Michael Gelband first reported a position in SRDX in Q2 2020 and held it in 7 quarters. The position peaked at $2.52M in Q3 2024. 146 funds tracked by Wall St. Rank hold SRDX as of Q3 2025.

  • Michael Gelband reported no remaining Surmodics position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 10,379 Surmodics shares in Q3 2025, an estimated $308K.
  • Michael Gelband first reported a position in Surmodics in Q2 2020 and held it in 7 quarters.
  • Michael Gelband's Surmodics position peaked at $2.52M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Surmodics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.